Analysis
May 2, 2025

Västra Hamnen Corporate Finance has published an analysis of Xintela.

Västra Hamnen Corporate Finance has published an analysis of Xintela.

Västra Hamnen Corporate Finance has published an analysis of Xintela.

Read more
Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

Events
Videos
Xintela in the news
Analyses
Apr 15, 2025
–
Apr 17, 2025
Cell & Gene meeting on the med, Rome (Italy)
Dec 12, 2024
–
Dec 14, 2024
4th Regenerative Medicine Orthopedic Summit, Miami
Nov 4, 2024
–
Nov 6, 2024
BIO-Europe, Stockholm, Sweden
Sep 25, 2024
–
Sep 27, 2024
7th ICRS Summit, Catania
Sep 18, 2024
–
Sep 20, 2024
EORS 2024, Aalborg
Sep 4, 2024
–
Sep 6, 2024
ISCT Europe 2024, Gothenburg
Jul 10, 2024
–
Jul 13, 2024
ISSCR 2024, Hamburg
Jun 3, 2024
–
Jun 6, 2024
BIO International Convention, San Diego
May 8, 2024
–
May 10, 2024
21st ESSKA Congress, Milan
Nov 30, 2023
–
Dec 2, 2023
3rd Regenerative Orthopaedic Summit by the Regenerative Medicine Orthopaedic Society (RMOS), Istanbul
Nov 21, 2023
–
Nov 23, 2023
43rd Orthopaedic World Congres by the International Society of Orthopaedic Surgery and Traumatology (SICOT), Cairo
Oct 10, 2023
–
Oct 12, 2023
2023 Cell & Gene Meeting on the Mesa, Carlsbad, October 10-12
Sep 9, 2023
–
Sep 12, 2023
- 17th world congress by the International Cartilage Regeneration & Joint Preservation Society (ICRS), Sitges/Barcelona
Jun 5, 2023
–
Jun 8, 2023
BIO International Convention, Boston
May 31, 2023
–
Jun 3, 2023
23rd European Congress of Rheumatology, by European Alliance of Associations for Rheumatology (EULAR), Milan
May 11, 2023
–
May 13, 2023
2nd Regenerative Orthopaedic Summit, Naples
May 12, 2023
–
May 13, 2023
10. Berliner Knorpelsymposium, Berlin
Apr 27, 2023
–
Apr 29, 2023
ICRS Focus Meeting on Allografts and synthetics on the frontstage, Nice
Apr 12, 2023
–
Apr 14, 2023
Cell & Gene Meeting on the Med 2023 Barcelona
Mar 17, 2023
–
Mar 20, 2023
OARSI world congress on osteoarthritis, Denver
–
Mar 16, 2023
BioStock Investor Meeting (broadcast online)
Mar 1, 2023
–
Mar 2, 2023
European Life Sciences CEO Forum (ELSF 2023) in Zürich, March 1-2, 2023
–
Feb 22, 2023
Redeye Theme: Regenerative Medicine / Cell Therapy, February 22, 2023
–
Jan 9, 2023
JPM Annual Healthcare Meeting 2023, San Francisco, January 9-12
–
Dec 1, 2022
1st Regenerative Orthopaedic Summit, Athens, December 1-3, 2022
–
Nov 29, 2022
BioStock Life Science Summit, Lund, November 29-30 2022
–
Nov 14, 2022
Investival Showcase, London, November 14, 2022
–
Nov 2, 2022
BioEurope (Digitalt), November 2-4, 2022
–
Oct 11, 2022
2022 Cell & Gene Meeting on the Mesa, Carlsbad, October 11-13
–
Oct 6, 2022
ICRS Focus Meeting, Bologna, October 6-7
–
Sep 28, 2022
Nordic Life Science Days, Malmö, September 28-29, 2022
–
Aug 30, 2022
2nd Integrin-Targeted Drug Development Summit, Boston, August 30 - September 1
–
Jun 13, 2022
Småbolagsdagarna, Stockholm, June 13-15
–
Jun 13, 2022
Bio International Convention, San Diego, June 13-16
June 1, 2023
ProHearings Capital Market Day

CEO Evy Lundgren-Åkerlund presents the company at ProHearings Capital Market Day in Stockholm on June 1, 2023.

‍

June 1, 2022
Xintela's CEO visits BioStock Studio

Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).

January 22, 2024
Targinta in BioStock
BioStock: Targinta’s CEO “Strong interest in ADCs in 2023”
June 1, 2023
Xintela in DIs #InvestTalks
DIs #InvestTalks - Xintela develops new generation stem cell products
May 30, 2023
Xintela in BioStock
BioStock: Xintela highlights the unique properties of XSTEM
May 2, 2023
Xintela in BioStock
BioStock: Xintela initiates last dose level in knee osteoarthritis study
March 22, 2023
Xintela in BioStock
BioStock: Targinta positions itself in the ADC field
July 6, 2022
Xintela in clinical development
BioStock: Xintela in clinical development
June 1, 2022
Xintela's CEO visits BioStock Studio
BioStock Studio: Xintela's CEO comments on the upcoming share issue
April 12, 2022
Xintela in BioStock
BioStock: Xintela's CEO on the potential in difficult-to-heal wounds
March 4, 2022
Article: Xintela in BioStock
BioStock: Xintela presents plans for 2022 in its Q4 report
January 27, 2022
Targinta's CEO visits BioStock Studio
BioStock Studio: Targinta provides business update prior to spin-off
January 19, 2022
Article: Xintela in BioStock
BioStock: Xintela advances to clinical phase in osteoarthritis and difficult-to-heal wounds 2022
October 12, 2021
Interview with Professor Folke Sjöberg
BioStock: Professor Folke Sjöberg about XSTEM for treatment of venous leg ulcers.
November 9, 2020
Article: Xintela in BioStock
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in Horsetalk.co.nz
Xintela covered in Horsetalk.co.nz regarding that its stem cells are safe for use in horses
March 23, 2016
Xintela in Investerarbrevet
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
Xintela covered in Life Science Sweden
(Article in Swedish) Xintela covered in Life Science Sweden
March 23, 2016
Xintela covered in 8till5
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
February 24, 2016
Xintela på väg till First North
(Article in Swedish) Rapidus: Xintela på väg till First North
May 2, 2025
Västra Hamnen Corporate Finance
Västra Hamnen Corporate Finance has published an analysis of Xintela.
November 29, 2024
VHCF Research update Q3 2024
Västra Hamnen Corporate Finance has published a research update for Q3 2024.
September 5, 2024
VHCF Research update Q2 2024
Västra Hamnen Corporate Finance has published a research update for Q2 2024
May 29, 2024
VHCF Research update Q1 2024
Västra Hamnen Corporate Finance has published a research update Q1 2024
March 13, 2024
VHCF Research update Q4 2023
Västra Hamnen Corporate Finance has published a research update for Q4 2023.
December 1, 2023
Västra Hamnen Corporate Finance analysis
Västra Hamnen Corporate Finance has published an initial analysis of Xintela.
December 10, 2021
Edison Group Analysis
Edison Group has published a research update on Xintela.
July 14, 2021
Xintela, backed by its integrin biomarke
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
Status Report Xintela
A status report of the Xintela has been published by Biostock
April 12, 2018
BioStock analysis
Read the full analysis here
Top
ABOUT XINTELAAbout the companyHistoryManagement team and BoardBusiness DevelopmentCareer possibilities
R&DTechnology PlatformPipelineStem cell therapyCancer therapyIndicationsPublications
INVESTORSShare informationOwner listPDMR transactionsFinancial CalendarReportsAnalysesCorporate GovernanceGeneral MeetingsShare IssuesSubscribeIR contactCertified Adviser
NEWS & MEDIAPress releasesXintela in the newsNewslettersEventsFilmsSubscribeArchive